Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
NVCR

NVCR - Novocure Ltd Stock Price, Fair Value and News

21.35USD-0.17 (-0.79%)Market Closed

Market Summary

NVCR
USD21.35-0.17
Market Closed
-0.79%

NVCR Alerts

  • Losses in recent quarter

NVCR Stock Price

View Fullscreen

NVCR RSI Chart

NVCR Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-12.01

Price/Sales (Trailing)

4.41

EV/EBITDA

-14.66

Price/Free Cashflow

-19.14

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

74.82%

EBT Margin

-32.78%

Return on Equity

-53.64%

Return on Assets

-17.19%

Free Cashflow Yield

-5.22%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

525.7M

Rev. Growth (Yr)

13.36%

Rev. Growth (Qtr)

3.53%

NVCR Earnings

Earnings (TTM)

-192.7M

Earnings Growth (Yr)

26.95%

Earnings Growth (Qtr)

17.67%

Breaking Down NVCR Revenue

Last 7 days

-2.8%

Last 30 days

5.9%

Last 90 days

54.0%

Trailing 12 Months

-52.2%

How does NVCR drawdown profile look like?

NVCR Financial Health

Current Ratio

6.26

Debt/Equity

1.59

Debt/Cashflow

-0.15

NVCR Investor Care

Shares Dilution (1Y)

1.32%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024525.7M000
2023522.5M507.7M504.0M509.3M
2022537.9M545.2M542.6M537.8M
2021527.2M544.8M545.8M535.0M
2020379.8M409.0M449.6M494.4M
2019269.3M294.5M321.8M351.3M
2018194.3M217.4M232.1M248.1M
2017104.7M125.2M153.6M177.0M
201640.9M52.3M65.0M82.9M
201519.9M24.3M28.7M33.1M
20140012.9M15.5M
201300010.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Novocure Ltd

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
stafford kristin
acquired
-
-
4,053
-
Jun 05, 2024
scannell timothy j
acquired
-
-
4,053
-
Jun 05, 2024
vernon w anthony
acquired
-
-
4,053
-
Jun 05, 2024
hung david
acquired
-
-
4,053
-
Jun 05, 2024
leung gabriel
acquired
-
-
4,053
-
Jun 05, 2024
groenhuysen wilhelmus cm
acquired
2,838,190
22.82
124,373
chief operating officer
Jun 05, 2024
ocean allyson j
acquired
-
-
4,053
-
Jun 05, 2024
hilleman jeryl l
acquired
-
-
4,053
-
Jun 05, 2024
madden martin j.
acquired
-
-
4,053
-
Jun 04, 2024
leung gabriel
sold
-23,025
23.8851
-964
-

1–10 of 50

Which funds bought or sold NVCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
465
465
-%
May 28, 2024
WFA Asset Management Corp
sold off
-100
-1,046
-
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.46
136,665
321,665
0.04%
May 16, 2024
Colony Group, LLC
added
72.86
652,000
1,458,000
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.28
-13,521
1,593,600
-%
May 16, 2024
JANE STREET GROUP, LLC
added
18.92
1,743,580
8,860,370
-%
May 16, 2024
Tidal Investments LLC
new
-
695,004
695,004
0.01%
May 15, 2024
TWO SIGMA ADVISERS, LP
reduced
-11.97
-1,913,080
22,490,000
0.05%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
15.51
3,308,190
19,121,100
0.01%
May 15, 2024
Palo Alto Investors LP
unchanged
-
393,336
8,782,620
0.99%

1–10 of 40

Are Funds Buying or Selling NVCR?

Are funds buying NVCR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVCR
No. of Funds

Unveiling Novocure Ltd's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.13%
9,759,087
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital international investors
8.3%
8,896,076
SC 13G/A
Feb 09, 2024
capital world investors
3.1%
3,276,996
SC 13G/A
Feb 09, 2024
blackrock inc.
8.2%
8,792,035
SC 13G/A
Dec 11, 2023
capital world investors
5.5%
5,834,080
SC 13G/A
Nov 09, 2023
baillie gifford & co
4.77%
5,095,777
SC 13G/A
Feb 13, 2023
capital world investors
12.3%
12,899,395
SC 13G/A
Feb 13, 2023
capital international investors
7.8%
8,155,909
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Novocure Ltd

View All Filings
Date Filed Form Type Document
Jun 10, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading

Peers (Alternatives to Novocure Ltd)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.18
5.21
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.89
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.87
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.05
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.63
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
249.1M
324.0M
0.65% -42.87%
-1.3
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.48
5.77% 8.23%

Novocure Ltd News

Latest updates
MarketBeat08 Jun 202412:25 pm
Defense World08 Jun 202410:36 am
Nasdaq10 May 202407:00 am
The Motley Fool9 months ago

Novocure Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue3.5%138,503133,784127,321126,051122,182128,429130,998140,866137,547133,213133,606133,517134,695143,953132,660115,925101,82899,23492,06286,71373,309
Cost Of Revenue3.5%33,68932,55632,09234,01829,61428,88829,74928,50327,72729,68730,20628,59926,38528,13628,39525,47424,49624,78622,90021,10619,814
Gross Profit3.5%104,814101,22895,22992,03392,56899,541101,249112,363109,820103,526103,400104,918108,310115,817104,26590,45177,33274,44869,16265,60753,495
Operating Expenses-4.3%146,334152,944153,474154,693152,817142,519125,860133,491110,626126,924111,952117,213108,398103,72589,24383,78380,71374,29565,30764,41159,613
  S&GA Expenses-6.7%55,20659,18857,96458,48851,16949,62941,39544,75037,88438,98232,58034,13831,35731,35929,36428,46128,83426,80423,83023,70822,333
  R&D Expenses-5.0%51,59854,30853,62355,42759,70454,82051,95657,07542,23456,93148,14150,31545,91644,00332,81829,91825,27123,74118,76619,45417,042
EBITDA Margin13.3%-0.32*-0.36*-0.29*-0.25*-0.21*-0.13*-0.12*-0.10*-0.08*-0.08*-0.01*0.03*---------
Interest Expenses100.0%2.00-23,35810,0238,7561.002,7841,194-2,228-1,70998.001.001.001.0016.001,8403,4153,4153,4523,4533,4153,379
Income Taxes-16.7%7,1188,5451,2633,5141,9814,7453,1596522,1328852,5911,4061,3943,9081,7552,396-9,765-5,852-6301,2273,661
Earnings Before Taxes17.9%-31,642-38,534-48,222-53,904-51,080-32,558-23,417-23,356-2,515-25,573-10,533-13,235-2,7348,82511,0394,051-5,813-1,5921,300-43.00-8,489
EBT Margin12.9%-0.33*-0.38*-0.37*-0.32*-0.25*-0.15*-0.14*-0.11*-0.10*-0.10*-0.03*0.01*---------
Net Income17.7%-38,760-47,079-49,485-57,418-53,061-37,303-26,576-24,008-4,647-26,458-13,124-14,641-4,1284,9179,2841,6553,9524,2601,930-1,270-12,150
Net Income Margin9.8%-0.37*-0.41*-0.39*-0.34*-0.27*-0.17*-0.15*-0.13*-0.11*-0.11*-0.05*-0.01*---------
Free Cashflow-102.8%-43,358-21,379-26,567-29,668-22,815-10,13816,71711,631-8,78013021,10323,554---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.2%1,1211,1461,1461,1591,1741,1921,1741,1631,1501,1391,1201,0971,0681,052431529502479444406370
  Current Assets-3.1%1,0031,0341,0481,0651,0891,1121,1021,0951,0811,0741,0691,0461,015999383488462440407370336
    Cash Equivalents88.4%454241155157186116244368192209691361326246235198183179210182154
  Inventory11.1%42.0038.0037.0033.0032.0029.0027.0030.0029.0024.0023.0027.0028.0027.0026.0026.0023.0024.0024.0025.0024.00
  Net PPE14.4%59.0051.0046.0041.0036.0033.0030.0027.0025.0023.0012.0012.0012.0011.0010.0011.0010.009.008.008.008.00
Liabilities-2.8%762784753743742750729721714729707700695575124261261262253247244
  Current Liabilities-10.5%16017915715014915914113512814312511611011495.0085.0084.0086.0080.0074.0071.00
  Long Term Debt0.1%570569568567566566565564563562561561560430-150149149149149149
    LT Debt, Non Current0.1%570569568567566566565564563562561561560430-150149149149149149
Shareholder's Equity-0.9%359362394416432441445442436410413397372477307268242218190159126
  Retained Earnings-3.9%-1,024-985-938-888-831-778-741-714-690-685-659-646-631-631-635-645-646-650-655-657-655
  Additional Paid-In Capital2.5%1,3881,3531,3341,3071,2661,2221,1891,1581,1281,1001,0741,0451,0061,111946917893871848818784
Shares Outstanding0.5%108107107107106105105105104103104103---------
Float----1,415---2,831---9,486---2,774---3,943-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-116.9%-31,574-14,558-19,314-22,737-16,727-3,70722,42015,762-3,68714,40424,40026,17217,78053,48130,96912,7411,9576,96214,9079,066-4,315
  Share Based Compensation95.5%34,08417,43826,34632,74039,08429,78226,30525,82325,04522,39825,75827,88118,86320,27320,12118,77016,55714,69714,33813,7329,649
Cashflow From Investing150.0%246,21698,50017,258-13,89782,287-128,060-150,244155,757-17,410-499,090302,703-2,61854,171-613,638147,218-3,315-3,112-46,756-2,174-1,748-989
Cashflow From Financing-88.8%2131,9101,1717,5025,2043,4104,2044,7363,1413,6523,03611,0597,955570,854-140,4935,3454,5038,58615,46820,65716,970
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NVCR Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Income Statement [Abstract]   
Net revenues$ 138,503$ 122,182$ 509,338
Cost of revenues33,68929,614128,280
Gross profit104,81492,568381,058
Operating costs and expenses:   
Research, development and clinical studies51,59859,704223,062
Sales and marketing55,20651,169226,809
General and administrative39,53041,944164,057
Total operating costs and expenses146,334152,817613,928
Operating income (loss)(41,520)(60,249)(232,870)
Financial income (expenses), net9,8789,16941,130
Income (loss) before income tax(31,642)(51,080)(191,740)
Income tax7,1181,98115,303
Net income (loss)$ (38,760)$ (53,061)$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)$ (0.36)$ (0.50)$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)$ (0.36)$ (0.50)$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)107,266,198105,667,072106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)107,266,198105,667,072106,391,178

NVCR Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 453,763$ 240,821
Short-term investments416,384669,795
Restricted cash3,6001,743
Trade receivables, net65,09161,221
Receivables and prepaid expenses21,47922,677
Inventories42,39138,152
Total current assets1,002,7081,034,409
LONG-TERM ASSETS:  
Property and equipment, net58,91751,479
Field equipment, net11,91111,384
Right-of-use assets32,99434,835
Other long-term assets14,89914,022
Total long-term assets118,721111,720
TOTAL ASSETS1,121,4291,146,129
CURRENT LIABILITIES:  
Trade payables84,31694,391
Other payables, lease liabilities and accrued expenses75,91484,724
Total current liabilities160,230179,115
LONG-TERM LIABILITIES:  
Long-term debt, net569,652568,822
Long-term leases25,60827,420
Employee benefit liabilities6,5668,258
Other long-term liabilities1818
Total long-term liabilities601,844604,518
TOTAL LIABILITIES762,074783,633
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:  
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 107,603,774 shares and 107,075,754 shares at March 31, 2024 (unaudited) and December 31, 2023, respectively00
Additional paid-in capital1,387,7651,353,468
Accumulated other comprehensive income (loss)(4,147)(5,469)
Retained earnings (accumulated deficit)(1,024,263)(985,503)
TOTAL SHAREHOLDERS' EQUITY359,355362,496
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 1,121,429$ 1,146,129
NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
 CEO
 WEBSITEnovocure.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES1320

Novocure Ltd Frequently Asked Questions


What is the ticker symbol for Novocure Ltd? What does NVCR stand for in stocks?

NVCR is the stock ticker symbol of Novocure Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novocure Ltd (NVCR)?

As of Thu Jun 13 2024, market cap of Novocure Ltd is 2.32 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers. The fair value of Novocure Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novocure Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novocure Ltd a good stock to buy?

The fair value guage provides a quick view whether NVCR is over valued or under valued. Whether Novocure Ltd is cheap or expensive depends on the assumptions which impact Novocure Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCR.

What is Novocure Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, NVCR's PE ratio (Price to Earnings) is -12.01 and Price to Sales (PS) ratio is 4.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCR PE ratio will change depending on the future growth rate expectations of investors.